Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 46
HOS-112169 · Präparat HOS-093615
The mechanism of interaction between atazanavir and ritonavir is CYP3A4 inhibition. Indinavir Indinavir is associated with indirect Co-administration of unconjugated hyperbilirubinaemia due to REYATAZ/ritonavir and inhibition of UGT. indinavir is not recommended (see section 4.4). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) Lamivudine 150 mg twice No significant effect on lamivudine and Based on these data and daily + zidovudine 300 mg zidovudine concentrations was observed. because ritonavir is not twice daily expected to have a significant (atazanavir 400 mg once daily) impact on the pharmacokinetics of NRTIs, the co-administration of these medicinal products and REYATAZ is not expected to significantly alter the exposure of the co-administered medicinal products. Abacavir The co-administration of abacavir and REYATAZ is not expected to significantly alter the exposure of abacavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lamivudine (HOS-085829) zidovudine (HOS-085837) ritonavir (HOS-084521) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage fdeedfc415df230cbb75abaad9beb2f47f8b9c6d5cfaf651d40b9c761cba8d6a · Zeichen 9954–11965 im Abschnitt